Healthcare [ 10/13 ] | Biotechnology [ 105/159 ]
NASDAQ | Common Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Apr 30, 24 | 0 Increased by +100% | -0.03 Increased by +100% |
Nov 13, 23 | -4.6 Decreased by -5.01 K% | -0.03 Decreased by -14.79 K% |
Aug 10, 23 | -0.04 Increased by +96.64% | -0.04 |
May 11, 23 | -0.27 Increased by +70.62% | -0.05 Decreased by -420.16% |
Mar 30, 23 | -1.38 Decreased by -69.3% | -0.05 Decreased by -2.57 K% |
Nov 11, 22 | -0.09 Increased by +87.55% | -0.09 |
Aug 18, 22 | -1.19 Decreased by -28.47% | -0.14 Decreased by -779.53% |
May 5, 22 | -0.91 Decreased by -73.82% | -0.52 Decreased by -76.95% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 23 | 327.73 K Decreased by -19.95% | -2.62 M Increased by +36.29% | Decreased by -798.54% Increased by +20.41% |
Jun 30, 23 | 630.88 K Increased by +244.08% | -2.68 M Increased by +62.95% | Decreased by -424.04% Increased by +89.23% |
Mar 31, 23 | 500.89 K Increased by +111.14% | -2.41 M Increased by +58.67% | Decreased by -480.58% Increased by +80.42% |
Dec 31, 22 | 592.43 K Increased by +49.04% | -3.65 M Increased by +17.46% | Decreased by -616.38% Increased by +44.62% |
Sep 30, 22 | 409.42 K Decreased by -39.97% | -4.11 M Decreased by -14.16% | Decreased by -1 K% Decreased by -90.16% |
Jun 30, 22 | 183.35 K Decreased by -81.53% | -7.22 M Decreased by -53.97% | Decreased by -3.94 K% Decreased by -733.5% |
Mar 31, 22 | 237.24 K Decreased by -71.9% | -5.82 M Decreased by -120.63% | Decreased by -2.45 K% Decreased by -685.12% |
Dec 31, 21 | 397.49 K Decreased by -78.17% | -4.42 M Decreased by -108.2% | Decreased by -1.11 K% Decreased by -853.64% |
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot"Marie"Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.